RaySearch enters research collaboration with Massachusetts General Hospital

RaySearch enters research collaboration with Massachusetts General Hospital

RaySearch Laboratories AB has signed a cooperation agreement with Massachusetts
General Hospital (MGH) in Boston, USA, covering research and development within
the field of multi-criteria optimization for radiation therapy. 

In all radiation treatments the clinician has to balance conflicting objectives
such as obtaining a sufficiently high target dose to achieve tumor control,
while ensuring that the dose to the surrounding healthy tissues is sufficiently
low to minimize the risk for side effects. Multi-criteria optimization provides
a tool for dealing with these tradeoffs in a stringent fashion. 

The goal of the cooperation is to develop a software product that enables
clinicians to explore and evaluate a representative set of treatment
alternatives in a highly intuitive and efficient way. This has the potential to
speed up the time-consuming treatment planning optimization process where
currently the different parameters of a treatment plan are changed through trial
and error until a satisfactory plan is found.

The MGH team is led by Harvard Medical School Professor, Dr. Thomas Bortfeld,
who is Director of Physics Research at the Massachusetts General Hospital
Department of Radiation Oncology.

“Our goal is to change the paradigm of radiation treatment planning by
implementing our multi-criteria planning concepts in hospitals, for the direct
benefit of the patients and the staff. In Raysearch we found the ideal partner
to accomplish this goal. We are looking forward to a fruitful co-operation with
the highly talented and professional people at Raysearch,” says Dr. Bortfeld. 

Johan Löf, President of RaySearch, adds: “We are delighted to have entered this
cooperation. Dr. Bortfeld is one of the world's leading authorities in the
radiation therapy research field and MGH is a great clinic offering a wide
spectrum of advanced radiation treatments. I am convinced that the cutting edge
research and solid clinical experience of MGH combined with our advanced
software engineering skills will provide an excellent foundation for developing
a very exciting product.”


FOR FURTHER INFORMATION, CONTACT:
Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com

ABOUT RAYSEARCH
RaySearch Laboratories is a medical technology company that develops advanced
software solutions for improved radiation therapy of cancer. RaySearch's
products are sold through license agreements with leading partners such as
Philips, Varian, Nucletron, IBA Dosimetry and TomoTherapy. Eight products have
been released to date and RaySearch's software is used at over 1,300 clinics in
more than 30 countries. In addition, existing license agreements cover more than
15 other products that are scheduled to be launched in the coming years.
RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in
Stockholm and the company is listed in the SmallCap segment on the OMX Nordic
Exchange Stockholm. 

For more information about RaySearch, visit www.raysearchlabs.com.